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dextran-coated superparamagnetic iron oxide
(SPIO) nanoworms in mouse versus human serum
Nirmal K Banda1, Gaurav Mehta1, Ying Chao2, Guankui Wang3, Swetha Inturi3, Liliane Fossati-Jimack4, Marina Botto4,
LinPing Wu5, Seyed Moein Moghimi5,6 and Dmitri Simberg3*Abstract
Background: The complement system is a key component of innate immunity implicated in the neutralization and
clearance of invading pathogens. Dextran coated superparamagnetic iron oxide (SPIO) nanoparticle is a promising
magnetic resonance imaging (MRI) contrast agent. However, dextran SPIO has been associated with significant
number of complement-related side effects in patients and some agents have been discontinued from clinical use
(e.g., Feridex™). In order to improve the safety of these materials, the mechanisms of complement activation by
dextran-coated SPIO and the differences between mice and humans need to be fully understood.
Methods: 20 kDa dextran coated SPIO nanoworms (SPIO NW) were synthesized using Molday precipitation procedure.
In vitro measurements of C3 deposition on SPIO NW using sera genetically deficient for various components of the
classical pathway (CP), lectin pathway (LP) or alternative pathway (AP) components were used to study mechanisms
of mouse complement activation. In vitro measurements of fluid phase markers of complement activation C4d and Bb
and the terminal pathway marker SC5b-C9 in normal and genetically deficient sera were used to study the mechanisms
of human complement activation. Mouse data were analyzed by non-paired t-test, human data were analyzed by
ANOVA followed by multiple comparisons with Student-Newman-Keuls test.
Results: In mouse sera, SPIO NW triggered the complement activation via the LP, whereas the AP contributes via
the amplification loop. No involvement of the CP was observed. In human sera the LP together with the direct
enhancement of the AP turnover was responsible for the complement activation. In two samples out of six healthy
donors there was also a binding of anti-dextran antibodies and C1q, suggesting activation via the CP, but that did not
affect the total level of C3 deposition on the particles.
Conclusions: There were important differences and similarities in the complement activation by SPIO NW in mouse
versus human sera. Understanding the mechanisms of immune recognition of nanoparticles in mouse and
human systems has important preclinical and clinical implications and could help design more efficient and
safe nano-formulations.Introduction
Superparamagnetic iron oxide (SPIO) is one of the most
widely cited metal oxide nanoparticle that has been used
as magnetic resonance imaging (MRI) contrast agent
alone and as a component of multifunctional nanomedi-
cines [1]. Dextran SPIO consists of magnetite-maghemite* Correspondence: dmitri.simberg@ucdenver.edu
3The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of
Colorado Anschutz Medical Campus, 12850 East Montview Blvd., Aurora, CO
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unless otherwise stated.(Fe3O4 and γ-Fe2O3) crystalline cores of 3–10 nm size
coated with dextran or carboxymethyl dextran [2]. Despite
the tremendous medical need in efficient MRI contrast
agents [3], several dextran SPIO formulations have been
withdrawn from the clinical use due to hypersensitivity in
patients (Sinerem, Combidex, Feridex). Another problem
of these nanomaterials is the propensity of dextran SPIO
for liver and spleen clearance, which limits imaging to
macrophage-rich organs. In order to design contrast agents
with reduced toxicity and improved pharmacokinetics,
a basic understanding of immune recognition of thesetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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systems of paramount importance.
The complement system accounts for about 5% of
globulins in serum and is responsible for recognition,
elimination and destruction of pathogens [4]. Activation
of the complement on the foreign surface takes place via
either the classical pathway (CP), the lectin pathway
(LP) or the alternative pathway (AP). The CP activation
is triggered via initial binding of IgG or IgM to the
pathogen surface, followed by binding and activation of
C1q component and formation of C4bC2a, a C3 con-
vertase. C4bC2a cleaves C3 into C3a and C3b, and the
latter covalently attaches via highly reactive thioester
group to hydroxyls and amines on the foreign surface
[5]. More C3b is formed through the alternative pathway
(AP) via the formation of alternative C3 convertase
C3bBb. Lectin pathway (LP) is somewhat different in mice
vs. humans. In mice, the activation is primarily triggered
via initial binding of mannose-binding lectin -A and -C
or ficolin A to carbohydrates on the pathogen surface,
leading to activation of MBL-associated serum protease
MASP-2 and formation of C4bC2a, the C3 convertase.
In humans, five different sugar recognition molecules
have been identified that are able to initiate the LP: MBL,
M-, L-, and H-ficolins; and collectin 11 (CL11 or CL-K1),
but the downstream activation of the classical C3 conver-
tase is believed to be similar in mice and humans [6].
Activation of the complement plays a major role in the
immune recognition of nanoparticles and pathogens [7].
Opsonization by C3b and its cleavage products (e.g.,
iC3b) triggers recognition by complement receptors CR3
(also known as CD11b/CD18 or Mac-1), complement
receptor CR4 (CD11c/CD18), and complement receptor
immunoglobulin (CRIg) [8,9], leading to particle uptake
by macrophages. Complement cleavage byproducts C3a
and C5a are among the most potent anaphylatoxins and
proinflammatory molecules with low nanomolar affinity
[10]. Many nanoparticulate systems including iron oxides
exhibit signs of the complement activation in vivo [11-20].
At the same time, despite the accumulating evidence on
the involvement of complement in acute and often life
threatening reactions observed in some patients infused
with dextran SPIO, the mechanisms of complement
activation are not clear. Our earlier report using shot-
gun proteomics demonstrated the absorption of the LP
components MBL-A/C and MASP-1/2 from mouse
plasma on the SPIO surface [21]. The involvement of
the LP in the complement activation would be a logical
assumption, since dextran is a polysaccharide and as
such may be recognizable via the LP [22]. This contrasts
the reported mechanisms of activation in human sera.
Pedersen et al. demonstrated that iron oxide nanoparticles
of large curvature activate the CP in human plasma
[13] due to the presence of specific anti-dextran IgMantibodies in certain individuals. In view of the above-
mentioned similarities and differences between mouse and
human complement systems, we set out to systematically
study the mechanisms and pathways of the complement
activation in mouse versus human sera. For the study below
we used our previously described 20 kDa dextran-coated
SPIO nanoworms (SPIO NW) that have physicochemical
and biological properties similar to Feridex [23,24]. Our
data suggest that SPIO NW activate complement in mouse
and human sera, but the mechanisms of activation are
different, which could bear important implications on
preclinical and clinical studies of these materials.
Results and discussion
Mechanisms of complement activation by SPIO in
mouse sera
Dextran SPIO contrast agents Feridex I.V.™ (Feridex) and
Sinerem™ have been discontinued due to safety issues and
are no longer available on the market. Although we used
Feridex in our earlier studies [25], the remaining amount
was not sufficient for a full scale complement study, and
therefore we used our previously described dextran-
coated SPIO nanoworms [23]. These nanoparticles are
prepared by precipitation of 20 kDa dextran with
FeCl2/FeCl3 using the established method of Molday
and MacKenzie [26]. The same method was used for
preparation of Feridex and other dextran SPIO [27,28],
with the difference being that for Feridex manufacturing
10 kDa (T-10) dextran was used, whereas we used 20 kDa
dextran. SPIO NW (Figure 1a and Additional file 1: Figure
S1) have a worm-like shape with multiple crystalline cores
(~6-7 nm each crystal) embedded in the dextran mesh-
work and with an average hydrodynamic diameter of
169 ± 77.43 nm and zeta potential of −6.05 ± 8.29 mV
(Figure 1a). Our previous studies showed that Feridex
and SPIO NW have similar physicochemical and im-
munological properties [24]. To verify the complement
activation by SPIO NW and Feridex in mouse serum,
we incubated the particles in normal mouse serum
at the concentration similar to the concentrations used
in vivo (100 μg/mL serum, or 4 mg/kg body weight),
washed multiple times by ultracentrifugation and analyzed
for the presence of complement fragments in serum
supernatant and on the purified particles. The binding and
activation of a complement leads to C3 cleavage and cova-
lent deposition of C3b via active thioester bond on the
pathogen surface. Main C3 fragments are schematically
shown in Figure 1b. The C3 deposition and the pattern
of C3 fragments on the surface of Feridex (Additional
file 2: Figure S2) were similar to those of SPIO NW.
Western blot analysis of fragments deposited on SPIO
NW revealed presence of C3b α1’ and α2’ chains
(Figure 1b lane 1), suggesting complement activation
with subsequent cleavage of C3b to iC3b by Factor I
Figure 1 SPIO-mediated complement activation in knockout mouse sera. (a) Model of worm-like polycrystalline SPIO NW shows magnetite/
maghemite crystals (10 nm, brown color) randomly coated with 20 kDa dextran chains (arrow). Size bar for transmission electron microscopy image:
100 nm; (b) scheme of C3 chains and cleaved fragments; (c) nanoparticles were incubated with normal mouse sera (C57BL/6) and C3 fragments were
detected on purified SPIO NW or in whole serum by western blotting. Fragments of C3 are clearly detected in purified SPIO NW sample. Zymosan
particles (1 mg/ml) also showed strong complement activation; (d) deposition of C3 fragments on SPIO NW surface as a function of normal serum
concentration as detected with dot blot immunoassay (see Methods); (e) deposition of C3 fragments in sera deficient for the LP components shows
complete dependency on the MBL-MASP-2 but not on FcnA. All experiments were repeated at least three times based on n = 3; (f) deposition of C3
fragments in normal mouse sera pre-incubated with different concentrations of the LP inhibitor mannose; (g) deposition of C3 fragments in sera
deficient for the AP. N = 3 for each bar, repeated at least 3 times. ***p < 0.0001, and **p < 0.01.
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concentration of C3 fragments, compared to the non-
treated sera (Figure 1c, lane 3). Zymosan (1 mg/mL) caused
complete disappearance of α chain in serum, suggesting
a much more potent activation of the complement than
SPIO NW (Figure 1c, lane 4). The reason for the shifted
position of α1’ chain eluted from SPIO NW could be due
to binding of α1’ chain via thioester to high molecular
weight components on the surface of SPIO NW (e.g.,
dextran). The reason for lack of detection of C3 β chain
(~70 kDa) on washed SPIO NW and zymosan treated
serum is not clear (albeit consistent), but could be due to a
weaker immunoreactivity of the antibody toward the eluted
β chain compared to the α chain fragments. Next, SPIO
NW were incubated with different dilutions of sera (80%,
40%, 20%) and washed using ultracentrifugation. Dot
blotting of washed SPIO NW on nitrocellulose membraneand immunodetection of C3 fragments showed linear
decrease in C3 fragment deposition with decrease in serum
concentrations (Figure 1d). There was no detectable C3
in the supernatant from the last wash of the nanoparticles,
suggesting that dot blot assay is detecting the nanoparticle
bound C3 fragments (shown in Figure 1c) and not the
carryover protein. In the subsequent experiments, we used
dot blot as the main method to quantify and compare the
complement activation in mouse sera and will refer to all
C3 fragments as “C3”.
In order to further investigate the pathways by which
SPIO NW trigger mouse complement we examined C3
fragment deposition after incubation of SPIO NW with
sera genetically lacking specific complement components.
The serum was mixed with SPIO NW at a final iron
concentration of 0.15 mg/ml and serum concentration of
75% v/v. There was a 97% decrease in C3 deposition in
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5 mM ethylenediamine tetraacetic acid (EDTA) (Figure 1e),
since complement activation via all pathways requires both
Ca2+ and Mg2+ ions. Also, there was not detectable C3
deposition in C3−/− serum. Activation of the LP proceeds
following the binding of serum MBL or the binding of
serum Ficolin A (FcnA) to a LP-activating surface [30].
There was 95% less C3 deposition in MBL-A/C−/− mouse
serum compared to normal mouse serum (Figure 1e).
There was a similar decrease in C3 deposition in the sera
lacking both MBL-A/C and FcnA (MBL-A/C−/−FcnA−/−),
and no decrease in FcnA−/− serum (Figure 1e), confirming
that complement activation in mouse serum depends
on MBL-A/C and not on FcnA. Three different types of
mannose-associated serine proteases (MASPs), i.e. MASP-
1, MASP-2 and MASP-3 have been reported to be asso-
ciated with MBL or ficolins in mouse sera [30,31]. In
order to confirm the role of the LP in the complement
activation, we measured C3 deposition using mouse
serum deficient for MASP-2. In MASP-2−/− mouse serum
there was a significant (p <0.05) 91% reduction in C3
deposition on the surface of SPIO NW (Figure 1e). At the
same time, there was no significant decrease in C3 depos-
ition in the C1q−/− serum (Figure 1e). C1q is required for
the initiation of the CP of complement. There was nearly
complete loss of C3 binding to SPIO NW in double
knockout MBL-A/C−/−C1q−/− serum, but no decrease
of C3 binding in C1q−/− serum compared to WT serum
(Figure 1d), suggesting that the CP plays a minor, if any
role, in mouse complement activation and C3 deposition.
On the other hand, mannose, which is the inhibitor of the
LP, decreased C3 deposition in a concentration-dependent
fashion (Figure 1f). Combined, these experiments confirm
the critical role of the LP in the complement activation on
SPIO NW in mouse serum.
To determine the role of AP in the complement activa-
tion and C3 deposition, we used sera genetically deficient
for critical components of the AP: factor D (FD) and
factor B (FB). Following the initial deposition of C3b, the
amplification via the AP takes place through the binding
of FB to C3b, subsequent cleavage into Bb by FD and for-
mation of C3bBb (alternative C3 convertase). According
to Figure 1g, the deposition of C3 in FB −/− serum as well
as in serum in which FB was immunochemically depleted
with a previously validated antibody [32,33] was 90%
less than that of WT serum. C3 deposition was also
decreased by 92% in the FD−/− serum and by 82% in
C1q−/−FD−/−serum. The higher deposition of C3 in the
C1q−/−FD−/−serum compared to FD−/− serum is interest-
ing and could suggest compensatory activity of the LP in
the double negative sera. C3 deposition in double negative
MBL-A/C−/−FD−/−− serum was decreased by 97% com-
pared to WT serum and by 6% compared to FD−/− serum.
Collectively, these experiments confirm that in mouse serathe complement activation is initiated mainly via the LP
and amplified via the AP, and that the amplification loop
adds the majority of C3 deposited on the surface of SPIO.
There is a possibility that MBL-A/C and/or MASP-1/2
could directly trigger the activation of the AP, as was
suggested previously [34,35], but we did not investigate
this hypothesis further. Some level of the complement
activation that is not inhibited in MBL A/C−/−FD−/−
serum is probably due to a baseline spontaneous C3
hydrolysis and formation of C3H2O but we did not
investigate this hypothesis further.
Mechanism of complement activation by SPIO NW in
human serum
Albeit mouse and human complement systems share
similarities, the relative contribution of pathways to the
complement activation could be different [36]. Therefore,
we determined the contribution of each of the pathways
using human serum. Since human sera deficient for the
complement factors and components are not readily avail-
able, we used a previously established combination of
depleted sera and purified complement factors [14]. In
addition, due to the availability of commercial quantitative
assays, we measured fluid phase markers rather than the
C3 deposition for measuring complement activation.
We examined the effect of SPIO NW concentration
on complement activation in a healthy human serum
(Figure 2a). The increasing concentration of SPIO NW
increased the level of the nonlytic soluble marker of the
terminal pathway (TP) of the complement (SC5b-9).
This is a sensitive measure of the activation of the whole
complement cascade in serum [18]. Notably, the com-
plement activation by SPIO NW was approximately 80%
more than by dextran alone at the similar concentration,
thereby confirming previous results [37,38]. Activation
of the CP and the LP requires divalent cations in the
form of Ca2+ and Mg2+, whereas Mg2+ is essential for
the operation of the AP [39]. The results in Figure 2b
demonstrate that SPIO-mediated complement activation
proceeds in serum supplemented with ethylene glycol
tetraacetic acid (EGTA)/Mg2+ (10.0 mM/2.5 mM), but
the generated levels of SC5b-9 are significantly (p <0.05)
lower (45% less) compared with normal serum. This
suggests that in addition to Ca2+-sensitive pathways (CP
and/or LP), there is also a direct enhancement of the AP
turnover activity. Following addition of SPIO NW to
normal sera, there was an elevation of the fluid-phase
alternative pathway marker Bb, confirming the role of the
AP in SPIO-mediated complement activation (Figure 2c).
SPIO-mediated complement activation through calcium-
sensitive pathways may also enhance the AP turnover
through the amplification loop of the alternative pathway
[39] but this was not investigated. In order to establish
through which calcium-sensitive pathways SPIO NW can
Figure 2 SPIO-mediated complement activation in defined human sera. (a) Effect of SPIO NW and dextran concentration on complement
activation, based on soluble C5b-9, in a typical human serum from a healthy Caucasian individual. SPIO NW concentration represents an equivalent
dextran concentration in the preparation. Zymosan (1 mg/ml) was used as positive control for monitoring complement activation; (b) contribution of
Ca2+-sensitive pathways and the AP turnover to dextran- and SPIO-mediated complement activation in the same serum as panel (a). The background
level with EGTA alone is similar to EGTA +Mg2+ (data not shown); (c) dextran and SPIO NW both enhanced the AP turnover as shown in panel as
monitored by Bb generation; (d) SPIO-mediated complement generation of C4d is independent of C1q suggesting involvement of the LP; (e) MBL is
required for SPIO-mediated triggering of the LP. The final concentration of iron in panels (b-e) was 200 μg/mL (equivalent dextran concentration).
C1qdepl and MBLdef represent sera immunochemically depleted from C1q and genetically deficient from MBL, respectively. MBL and L-ficolin
concentrations are shown in for C1qdepl and MBLdef sera. We used serum from a human donor with high titer of MBL to purify MBL/MASP
complexes. The same serum was used to deplete C1q. In experiments where we added MBL/MASP to a serum genetically deficient in MBL, the final
equivalent concentration of MBL was 1330 ng/mL (to resemble average MBL concentration in human serum) *p < 0.05, and **p < 0.01.
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genetically deficient MBL (MBLdef ) human sera [14]. The
immunochemically depleted C1q serum contained physio-
logical levels of the LP initiators (MBL and L-ficolin) [14].
SPIO NW (200 μg/mL) was capable to enhancing C4d
(the cleavage product of C4 and an established marker of
both CP and LP activation [14,18,39]) release in C1qdepl
serum compared with the background level, and further
addition of C1q to serum (180 μg/mL, corresponding
to physiological levels [14]) did not elevate serum levels
of C4d (Figure 2d). This strongly suggests that SPIO-
mediated calcium-sensitive complement activation is
exclusively through the LP. Activation of the LP in human
sera proceeds following either the binding of serum MBL
or L-ficolin to a LP activating surface [14,40] with subse-
quent activation of MASP-2 and cleavage of C4. There
was no increase in the C4d levels following addition of
SPIO NW to the MBLdef serum, whereas addition ofpurified MBL/MASP-2 complexes resulted in significant
(p <0.05) C4d generation. Since the MBLdef serum con-
tained physiological levels of L-ficolin, this eliminates a
role for L-ficolin in SPIO-mediated activation of the LP.
On the basis of these experiments, we therefore conclude
that SPIO NW activate complement through MBL-
mediated LP as well as the direct AP involvement.
Despite the fact that SPIO NW did not show any
activation of the CP in human sera that we tested so
far, several previous studies demonstrated the presence
of anti-dextran antibodies in sera of some individuals
[13,41] and the involvement of the CP on the surface of
nanoparticles due to the presence of anti-dextran IgM
antibodies was suggested [13]. We tested sera from six
healthy donors for anti-dextran antibodies, C1q depos-
ition and correlation with C3 deposition (Figure 3a). In
two out of six samples there was a significant binding
of antibodies to SPIO, and only in donor 1 the binding
Figure 3 SPIO NW mediated complement activation in normal human sera from different donors. Nanoparticles were incubated in human sera
as described for mouse experiments, washed and the deposition of proteins was detected with dot blot assay. (a) Anti-dextran antibody deposition of
SPIO NW in sera of six donors shows that only serum of donor 1 contained a significant amount of anti-dextran antibody as verified by inhibition with
free 20 kDa dextran (sample labeled as 1/dex); (b) C1q dot blot shows significant dextran-dependent deposition in donor 1; (c) C3 deposition shows
significant level of complement activation in all six serum samples; (d) there was no significant correlation between C1q binding and C3 deposition on
SPIO; (e) binding of MASP-2 to SPIO NW in human sera. All data represent a mean+ SEM of triplicates and the experiments were repeated at least two
times. All six samples were from non-smoking, <35 years old Caucasian male subjects.
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suggesting specificity (Figure 3b). Also, in the same sample
we also observed the binding of C1q that was inhibited by
free dextran, suggesting that the CP could be involved
in complement activation in sera from that individual
(Figure 3c). However, there was no significant correlation
(Spearman coefficient 0.08671) between C1q and C3
deposition in the six samples (Figure 3d). At the same
time, all serum samples showed similar binding of MASP-
2 (Figure 3e) suggesting the binding of the LP components
and possible involvement of the LP in all samples. It could
be suggested that in sera of individuals who have high
titres of antibodies against dextran there is an activation
of the CP (in addition to the LP and the AP).
The initial steps of complement activation and C3b
deposition in mouse vs. man are summarized in Figure 4.
Our experiments unambiguously demonstrate that SPIO
NW trigger complement activation in both mouse and
human sera. However, the relative contribution of the
pathways is different in mice and humans. In mouse sera,
we found that the complement is triggered via the LP, and
we did not find evidence for a significant role of the CP.
The fact that there was ~50-fold higher C3 deposition
in C1q−/− serum compared to MBL-A/C−/−C1q−/− serum
suggests the predominant contribution of the LP in the
complement activation. However, the classical pathway is
unstable in mouse sera upon storage and is also highly
variable [42], therefore some involvement of the CP inmice cannot be completely ruled out. In humans, the
contribution of the CP via anti-dextran antibodies is
possible in some individuals, as reflected in Figure 4.
The most important difference between mouse and
human complement, however, is the direct involvement
of the AP turnover independently of the LP in human
serum. Direct activation of the AP turnover has been
demonstrated for Listeria pathogen [43]. There is also a
distant possibility regarding the direct activation of the
AP by the LP components, in C2 and C4-dependent
and independent fashion [34,35,44], and this aspect will
be addressed in a separate study. Lastly, while in mice
the experiments in knockout sera indicated the direct
involvement of the MBL-A/C and MASP-2, the situation
in humans is more complicated. To date, multiple lectins
(e.g., MBL, collectins), ficolins and MASPs have been
shown to initiate the LP in human sera [30,45,46], and the
role of these factors in the complement activation by SPIO
NW remains to be elucidated.
Major questions regarding the interaction between
nanoparticle surface chemistry and the complement com-
ponents still remain. Thus, MBLs bind to wide range of
sugars, including mannose and glucose [22], and it is likely
that lectins also bind to the dextran coat on SPIO, but at
this point we did not investigate the exact mechanisms
of assembly of the LP components on the nanoparticle
surface. One interesting possibility could be that MBLs
bind to serum protein corona, rather than through
Figure 4 Summary of the initial steps of complement activation on SPIO NW surface: mouse vs. man. There is an involvement of the LP
in both mouse and human sera. The main difference is the direct involvement of the AP turnover in human sera, and activation of the CP in
some human individuals. The role of multiple LP components in humans is not clear at this point.
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how dextran structure and molecular weight affect the
assembly of the complement components, and whether
the relative contribution of the pathways depends on
the nanoparticle chemistry. Several studies failed to
demonstrate a conclusive correlation between molecu-
lar weight of dextran and the complement activation by
polymeric nanoparticles, with dextran conformation
(“loops and trains” vs. “end-on”) postulated as being the
most important factor in the activation efficiency [37,38].
The role of nanoparticle surface properties in the comple-
ment activation needs to be rigorously addressed in future
studies.
In conclusion, our results reveal important similarities
and differences between preclinical (mouse) and clinical
(human) systems with respect to complement activation
by SPIO NW. It is plausible to suggest that the observed
immunological behavior of SPIO NW could be applied to
Feridex and other variants of dextran SPIO nanoparticles.
Although Feridex and other dextran SPIO have been
discontinued from the clinical use, the results of our studyare critically important for development of new, more safe
MRI contrast agents. In that regard, it is clear from our
studies that strategies to reduce complement activation by
nanoparticles in a mouse system might not necessarily
translate into a human system. Mechanistic studies of
nanoparticle immune recognition should become an integral
part of nanomedicine research and development in order to
advance nanomedicine to a new level.
Methods
Nanoparticle synthesis and characterization
SPIO NW was prepared by precipitation of Fe2+ and Fe3+
salts in ammonia in the presence of branched dextran
of 20 kDa Mw (Sigma), as described elsewhere in the
literature [27,28,47]. Particles were re-suspended in
phosphate buffered saline (1xPBS) at 1–2 mg (Fe)/ml
and filtered through a 0.2 μm membrane filter. Nano-
particle size (intensity distribution) was measured using
a Zetasizer Nano (Malvern Instruments, Worcestershire,
UK). For nanoparticle imaging with transmission electron
microscopy, the nanoparticle solution in water was placed
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CA, USA). After 5 min, the grid was gently blotted and
air-dried. All the samples were studied without coun-
terstaining. Grids were viewed using a JEOL 1200EX II
transmission electron microscope at 75 kV and different
instrumental magnifications. Images were captured using
a Gatan digital camera.Complement activation in mouse sera
In all these studies sera from WT or knock out mice
on C57BL/6 J background were used. Mouse sera were
collected as described [48] according to the protocols
approved by the IACUC (Institutional Animal Care
and Use Committee) and stored at or below −70°C
before use. Each serum sample was subjected less than
2 freeze-thaw cycles, and aliquots were used whenever
possible. C3 deposition on SPIO NW was determined
by immunoblotting following incubation in normal sera
or sera deficient for complement factors and components
(obtained from the corresponding mice homozygous
for the gene deficiencies [32,33,49-52]). SPIO NW (final
concentration 0.4 mg iron/ml in 1× PBS) was incubated
with different dilutions of mouse sera (normally 10 μl
particles and 30 μl serum) and incubated for 10–30 min at
either room temperature of 37°C. Following incubation,
the nanoparticles were washed with 1 ml PBS (without
calcium or magnesium) four times by ultracentrifugation
(Beckman TLA-100 ultracentrifuge, TLA-100.3 rotor,
55.000 rpm for 10 min) and resuspended in PBS at
0.5 mg/ml. As a washing quality control, a separate tube
with serum but without nanoparticles was washed using
the exact same procedure. Zymosan (2 × 109 particles/mL)
was prepared by boiling 4 mg/mL solution of zymosan
(Sigma Aldrich) in normal saline for 60 min, washing in
PBS twice and resuspending in PBS + 0.1% sodium azide.
For dot-blot assay, nanoparticles (1 μl, 0.5 μg iron)
were spotted onto a 0.22 μm nitrocellulose membrane
(Bio-Rad) in triplicates. The membrane was dried and
blocked in 5% dry milk solution in Tween-20/PBS buffer.
For western blotting, particles were boiled at 90°C for
5 min in the reducing sample buffer (Bio-Rad), loaded on
a Tris-Glycine 4-20% minigel (Life Technologies), the
proteins were separated and transferred to a nitrocellulose
membrane using iBlot apparatus (Life Technologies). C3
on the membrane was detected with goat anti-mouse
C3 polyclonal antibody (MP Biomedicals) and donkey
anti-goat 800CW antibody (Li-COR Biosciences, Lincoln,
NE). Membranes were scanned at 800 nm with Li-COR
Odyssey scanner and the integrated C3 density of each
dot was calculated with the NIH ImageJ software. The dif-
ferences in the C3 deposition between sera were analyzed
with non-paired two-sided t-test at 95% CI using Prism
software (GraphPad, San Diego).Complement activation in human sera
Human sera were either commercially obtained or collected
according to the pre-approved IRB (Instutional Review
Board) protocol. Details for preparation, characterization
and functional assessments of complement pathways as
well as determination of MBL and L-ficolin concentra-
tions in normal human serum, C1q-depleted serum and
MBL-deficient serum were in accordance with our pre-
vious studies [14,39,53]. MBL/MASP-2 preparation and
characterization was described previously [54]. To meas-
ure complement activation in vitro, we determined SPIO-
and dextran-induced rise of serum complement activation
products C4d, Bb and SC5b-9 using respective ELISA kits
(Quidel, San Diego) according to the manufacturer’s pro-
tocols as described previously [14,18,39,53]. For measure-
ment of complement activation, the reaction was started
by adding the required quantity of SPIO NW (or dextran)
to undiluted serum in Eppendorf tubes (either in duplicate
or triplicate, depending on experiment) in a shaking water
bath at 37°C for 30 min, unless stated otherwise. Reactions
were terminated by addition of ‘sample diluent’ provided
with assay kits or saline containing 25 mM EDTA. Serum
complement activation products were measured following
nanoparticle removal by centrifugation. Control incuba-
tions contained saline (the same volume as SPIO) for
background measurement of complement activation prod-
ucts. In some experiments, SPIO-mediated complement
activation was monitored in the presence of EGTA/Mg2+
(10.0 mM/2.5 mM) as well as following restoration of
serum with deficient complement protein. Zymosan
(1 mg/mL) was used as a positive control for complement
activation throughout. For quantification of complement
activation products, standard curves were constructed
using the assigned concentration of each respective
standard supplied by manufacturer and validated as
described earlier [14,18,39,53]. The efficacy of SPIO NW
(or dextran) treatments was established by comparison with
baseline levels using paired t-test; correlations between two
variables were analysed by linear regression, and differences
between groups (when necessary) were examined using
ANOVA followed by multiple comparison with Student-
Newman-Keuls test.
Binding studies of anti-dextran antibody, C1q and C3 in
human sera was performed on samples from non-smokers,
age <35, males, white. Particles were incubated with
sera, washed in PBS with 2 mM Ca2+/Mg2+ (for C1q) or
in Ca2+/Mg2+ free PBS (for C3 and antibody), and immu-
noblotted as described above. Anti-dextran antibody
was detected using IRDye 800CW (Li-COR) labeled
anti-human antibody that is reactive with both IgG and
IgM, C1q was probed with goat anti-human/mouse
C1q (Santa Cruz Biotechnology) and then detected with
donkey anti-goat IRDye 800CW, C3 was probed with
goat anti-human C3 (MP Biomedicals) and detected
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of the spots was calculated with ImageJ. For dextran
inhibition studies, sera were preincubated with 10 mg/mL
of 20 kDa dextran for 5 min prior to addition of nano-
particles. Correlation between C3 and C1q deposition was
determined with Spearman two-tailed non-parametric test
with 95% confidence interval.
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